共 8 条
- [1] The development of costs for antidiabetics in statutory and private health insurance in Germany - an analysis of selected influencing factors JOURNAL OF PUBLIC HEALTH-HEIDELBERG, 2020, 28 (03): : 305 - 311
- [2] The development of costs for antidiabetics in statutory and private health insurance in Germany — an analysis of selected influencing factors Journal of Public Health, 2020, 28 : 305 - 311
- [3] Effects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany: differences and similarities JOURNAL OF PUBLIC HEALTH-HEIDELBERG, 2025,
- [4] The population perspective in assessing the performance of Germany's health care system: Results of a cross-sectional survey among members of a statutory health insurance ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN, 2024, 187 : 22 - 33